Wielenga, J J <br/><br/>
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.  [electronic resource] 

 -  Leukemia  Jan 1996 
 - 43-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Combined Modality Therapy<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Female<br/>Humans<br/>Interleukin-3--administration & dosage<br/>Leukemia, Myeloid, Acute--blood<br/>Leukocyte Count<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Platelet Count<br/>Recombinant Proteins--administration & dosage<br/>Recurrence<br/>Remission Induction